SL-279252

N/A

Report date: 2025/02/27 11:35:22
First In Class

Base Information

Drug NameSL-279252
Drug Alias NamePD1-Fc-OX40LTAK-252SL-279252
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 agonistsProgrammed death-ligand 1 blockers
TargetsTumor necrosis factor receptor superfamily member 4Programmed death-ligand 1
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesShattuck Labs IncTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShattuck Labs IncTakeda Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[15] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A